The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis

Cancer Gene Therapy

Volumn 4, Issue 4, 1997, Pages 239-245

  Buller, Richard E ^a   Sood, Anil ^a   Fullenkamp, Colleen ^a   Sorosky, Joel ^a   Powills, Karen ^a   Anderson, Barrie ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Gene therapy; Ovarian cancer; p53

Indexed keywords

PROTEIN P53;

ADULT; ALLELE; ANIMAL; ARTICLE; CHICK EMBRYO; CODON; FEMALE; GENETIC POLYMORPHISM; GENETICS; HUMAN; MIDDLE AGED; MUTATION; OVARY TUMOR; PATHOPHYSIOLOGY; PROGNOSIS;

ADULT; ALLELES; ANIMALS; CHICK EMBRYO; CODON; FEMALE; HUMANS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; POLYMORPHISM, GENETIC; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031180739     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Diller L, Kassel J, Nelson CE, et al. p53 functions as a cell cycle control protein in osteosarcoma. Mol Cell Biol. 1990;10:5772-5781.
2. Kastan MB, Onyekwere O, Sidransky D, et al. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991;51:6304-6311.
3. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene. 1993;8:307-318.
4. Levine AJ, Perry ME, Chang A, et al. The 1993 Walter Hubert Lecture: the role of the p53 tumor-suppressor gene in tumorigenesis [Review]. Br J Cancer. 1994;69: 409-416.
5. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989;342:705-708.
6. Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the p53 tumor suppressor gene: clue to cancer etiology and molecular pathogenesis [Review]. Cancer Res. 1994; 54:4855-4878.
7. Li FP, Fraumeni JF Jr, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988;48: 5358-5362.
8. Srivastava S, Zou Z, Pirollo K, et al. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature. 1990;348:747-749.
9. Clinical protocols. Cancer Gene Ther. 1994;1:289-295.
10. Roth JA, Nguyen D, Lawrence DD, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med. 1996;2:985-991.
11. Weston A, Pcrrin LS, Forrester K, et al. Allelic frequency of a p53 polymorphism in human lung cancer. Cancer Epidemiol Biomarkers Prev. 1992;1:481-483.
12. Olschwang S, Laurent-Puig P, Vassal A, et al. Characterization of a frequent polymorphism in the coding sequence of the Tp53 gene in colonic cancer patients and a control population. Hum Genet. 1991;86:369-370.
13. de la Culle-Martin O, Fabregat V, Romero M, et al. AccII polymorphism of the p53 gene. Nucleic Acids Res. 1990;18: 463.
14. Ara S, Lee PSY, Hansen MF, et al. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res. 1990;18: 4961.
15. Kawajiri K, Nakachi K, Imai K, et al. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis. 1993;14:1085-1089.
16. Zhang W, Hu G, Deisseroth A. Polymorphism at codon 72 of the p53 gene in human acute myelogenous leukemia. Gene. 1992;117:271-275.
17. Harris N, Brill E, Shohat O, et al. Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol. 1986;6:4650-4656.
18. Matlashewski GJ, Tuck S, Pim D, et al. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol. 1987;7:961-963.
19. DiSaia PM, Creasman WT. In: Bircher S, Gunter A, eds. Clinical Gynecologic Oncology, 4th ed. St. Louis, Mo: CV Mosby; 1993:336.
20. Lynch HT, Watson P, Bewtra C, et al. Hereditary ovarian cancer. Cancer. 1991;67:1460-1466.
21. Dunn J, Farndon JR. Familial breast cancer. J R Coll Surg Edinb. 1991;36:147-151.
22. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66-71.
23. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994;265:2088-2090.
24. Knutson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971;68:820-823.
25. Leach FS, Nicolaides NC, Papadopoulos N, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell. 1993;75:1215-1225.
26. Ponder B. Carcinogenesis. Is imprinting to blame? Nature. 1989;340:264.
27. Buller RE, Skilling JS, Kaliszewski S, et al. Absence of significant germ line p53 mutations in ovarian cancer patients. Gynecol Oncol. 1995;58:368-374.
28. Buller RE, Anderson B, Connor JP, et al. Familial ovarian cancer. Gynecol Oncol. 1993;51:160-166.
29. Skilling JS, Sood A, Niemann T, et al. An abundance of p53 null mutations in ovarian cancer. Oncogene. 1996;13: 117-123.
30. Skilling JS, Powills K, Lager DJ, et al. p53 allelotypes and enhanced detection of allelic loss in ovarian cancer: lack of correlation with familial and clinical factors. Gynecol Oncol. 1996;61:180-188.
31. Schildkraut JM, Risch N, Thompson WD. Evaluating genetic association among ovarian, breast, and endometrial cancer: evidence for a breast/ovarian cancer relationship. Am J Hum Genet. 1989;45:521-529.
32. Narod SA, Madlensky L, Bradley L, et al. Hereditary and familial ovarian cancer in Southern Ontario. Cancer. 1994; 74:2341-2346.
33. Bewtra C, Watson P, Conway T, et al. Hereditary ovarian cancer: a clinicopathological study. Int J Gynecol Pathol. 1992;4:180-187.
34. Miller BA, Ries LAG, Hankey BF, Kosary CL, Edwards BK, eds. Cancer Statistics Review, 1973-1989, NIH Pub. No. 92-2789. Washington, DC: National Cancer Institute; 1992.
35. Shiao Y-H, Chen VW, Scheer WD, et al. Racial disparity in the association of p53 gene alterations with breast cancer survival. Cancer Res. 1995;55:1485-1490.
36. Eley JW, Hill HA, Chen VW, et al. Racial differences in survival from breast cancer. JAMA. 1994;272:947-954.
37. Liu JR, Conaway M, Rodriguez GC, et al. Relationship between race and interval to treatment in endometrial cancer. Obstet Gynecol. 1995;86:486-490.
38. Kohler ME, Carney P, Dodge R, et al. p53 overexpression in advanced-stage endometrial adenocarcinoma. Am J Obstet Gynecol 1996;175:1246-1252.
39. Parker SL, Tong T, Bolden S, et al. Cancer Statistics, 1996. CA. 1996;46:5-27.
40. Gonzalez FJ. Genetic polymorphism and cancer susceptibility: fourteenth Sapporo cancer seminar. Cancer Res. 1995;55:710-715.
41. Vogelstein B, Kinzler KW. X-rays strike p53 again. Nature. 1994;370:174-175.
42. Zastawny RL, Salvino R, Chen J, et al. The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53. Oncogene. 1993;8:1529-1535.
43. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995;80:293-299.
44. Thor AD, Moore DH, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker or prognosis in breast cancers. J Natl Cancer Inst. 1992;84:845-855.
45. Marks JR, Davidoff AM, Kerns BJ, et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res. 1991;51:2979-2984.
46. Hartmann LC, Podratz KC, Keeney GL, et al. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol. 1994;12:64-69.